Elahere is a prescription medication used to treat adult patients with folate receptor-alpha (FRα) positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer. It is typically used after one to three prior treatments have been tried.
Mirvetuximab soravtansine Gynx
Generic Name/API:Mirvetuximab soravtansine-gynx
Packaging:One single-dose vial containing 100 mg of mirvetuximab soravtansine-gynx in 20 mL (5 mg/mL) of sterile solution.
Storage:store in a refrigerator at 2°C to 8°C
Dosage:6 mg/kg adjusted ideal body weight administered once every 3 weeks (21-day cycle) as an intravenous infusion.
Strength:100 mg/20 mL (5 mg/mL) of Elahere in a single-dose vial.
Indication:ELAHERE is approved for the treatment of adult patients with folate receptor-alpha (FRα) positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received one to three prior systemic treatment regimens. These cancers are closely related and typically treated the same way. "Platinum-resistant" is cancer that has returned or not responded within six months of platinum-based chemotherapy. FRα is a protein found on the surface of certain cancer cells, and Elahere targets this protein to deliver its anti-cancer effect directly to the tumor. This therapy is intended for patients whose cancer has progressed despite previous treatments and who test positive for FRα expression.
Elahere is a prescription medication used to treat certain types of ovarian cancer, specifically folate receptor alpha (FRα)-positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer. It is an antibody-drug conjugate that targets cancer cells by binding to the FRα protein, delivering a chemotherapy agent directly to the tumor.
Elahere is typically used in patients who have received prior treatments and whose cancer has returned or not responded to standard therapies.
Strength:
100 mg/20 mL (5 mg/mL) of mirvetuximab soravtansine-gynx in a single-dose vial.
Dosage:
The recommended dosage is 6 mg/kg adjusted ideal body weight administered once every 3 weeks (21-day cycle) as an intravenous infusion until disease progression or unacceptable toxicity.
Side effects:
- Eye problem
- Pneumonitis
- Peripheral neuropathy
Storage:
- Store vials upright in a refrigerator at 2°C to 8°C (36°F to 46°F).
- Protect from light.
- Do not freeze or shake.
-
Ocular side effects such as keratopathy, visual impairment, dry eyes, and uveitis may occur during Elahere treatment. Use of lubricating and ophthalmic steroid eye drops is recommended. Avoid contact lenses during treatment.
-
Fatal interstitial lung disease, including pneumonitis, can occur. Patients should be closely monitored for signs and symptoms.
-
Weakness, numbness, and pain, especially in the hands and feet, may occur during treatment.
-
Pregnant women should be informed of potential risks to the fetus. Women of reproductive potential should use contraception during treatment and for 7 months after the last dose.
FAQ
How does Elahere work?
Elahere is an antibody-drug conjugate. It combines a monoclonal antibody that targets the FRα protein on cancer cells with a chemotherapy agent. This allows the drug to deliver the chemotherapy directly to the cancer cells, helping to minimize damage to healthy cells.
How is Elahere given?
Elahere is administered through an intravenous (IV) infusion, usually given once every three weeks.
Can pregnant women take Elahere?
Elahere is not safe during pregnancy. It may harm an unborn baby. Women of reproductive potential should use effective contraception during treatment and for 7 months after the last dose.
What are the key criteria for selecting a supplier?
While selecting a supplier, we essentially ensure that the supplier holds a valid Good Distribution Practice (GDP) certification and possesses a valid operating license. These credentials confirm the supplier’s adherence to international standards for the proper distribution of medicinal products.
Whatis the cost of Elahere (mirvetuximab soravtansine gynx) in India?
The cost of Elahere (Mirvetuximab Soravtansine-gynx) varies as it’s not approved in India and must be imported. Factors like international currency exchange rates (USD/EUR), import duties, and supplier availability influence the final price. For the latest pricing and details, please contact 24/7 QualityMeds.
How to buy elahere (mirvetuximab soravtansine gynx) in India?
To buy elahere (mirvetuximab soravtansine-gynx) in India at a genuine price, contact 24/7 QualityMeds. We assist you in importing this medication legally and at the best possible cost.
